Business Context and Reporting Period
This Form 8-K Current Report from Achieve Life Sciences, Inc. (ACHV) covers events occurring on July 2, 2026, specifically the Company's Annual Meeting of Stockholders. The report details the ratification of corporate governance matters and a significant amendment to the Company's Certificate of Incorporation filed on July 6, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and voting results rather than financial performance data.
Material Changes and Voting Results
The following material actions were approved by stockholders at the Annual Meeting:
- Board Election: Nine directors were elected to serve until the next annual meeting. All nominees received majority support, with "For" votes ranging from approximately 46.3 million to 48.1 million shares.
- Accounting Firm Ratification: PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 68.6 million votes "For" and 198,133 votes "Against".
- Executive Compensation: The non-binding advisory vote on executive compensation was approved with 46.4 million votes "For" and 610,744 votes "Against".
- Capital Structure Amendment: Stockholders approved an amendment to increase the number of authorized common shares from 150,000,000 to 300,000,000. This proposal received 64.8 million votes "For" and 3.4 million votes "Against".
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies. The document serves as a procedural record of the Annual Meeting outcomes and the subsequent filing of the Certificate of Amendment with the State of Delaware.
Investor Verification Checklist
- Verify the effective date of the Certificate of Amendment increasing authorized shares to 300,000,000.
- Confirm the tenure of the newly elected board members and any changes to board composition.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for any additional provisions beyond the share increase.
- Check subsequent filings for any immediate impact of the increased share authorization on capital raising activities.